Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

XTL Biopharmaceuticals

DB:H2K2
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
H2K2
DB
₪20M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
  • XTL Biopharmaceuticals has significant price volatility in the past 3 months.
H2K2 Share Price and Events
7 Day Returns
-19.3%
DB:H2K2
-0.7%
DE Biotechs
-0.6%
DE Market
1 Year Returns
-61.8%
DB:H2K2
-13.2%
DE Biotechs
-20.9%
DE Market
H2K2 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
XTL Biopharmaceuticals (H2K2) -19.3% -27.7% -37.6% -61.8% -65.8% -93%
DE Biotechs -0.7% -8.2% -21% -13.2% 13.2% -11.8%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • H2K2 underperformed the Biotechs industry which returned -13.2% over the past year.
  • H2K2 underperformed the Market in Germany which returned -20.9% over the past year.
Price Volatility
H2K2
Industry
5yr Volatility vs Market

Value

 Is XTL Biopharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for XTL Biopharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €0.73.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for XTL Biopharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are XTL Biopharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:H2K2 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $0.00
TASE:XTLB Share Price ** TASE (2020-04-03) in ILS ₪0.04
TASE:XTLB Share Price converted to USD reporting currency Exchange rate (ILS/ USD) 0.275 $0.01
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 40.67x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of XTL Biopharmaceuticals.

DB:H2K2 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TASE:XTLB Share Price ÷ EPS (both in USD)

= 0.01 ÷ 0.00

-4.1x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XTL Biopharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • XTL Biopharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does XTL Biopharmaceuticals's expected growth come at a high price?
Raw Data
DB:H2K2 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.1x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.62x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for XTL Biopharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on XTL Biopharmaceuticals's assets?
Raw Data
DB:H2K2 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.01
TASE:XTLB Share Price * TASE (2020-04-03) in ILS ₪0.04
TASE:XTLB Share Price converted to USD reporting currency Exchange rate (ILS/ USD) 0.275 $0.01
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.33x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:H2K2 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TASE:XTLB Share Price ÷ Book Value per Share (both in USD)

= 0.01 ÷ 0.01

0.79x

* Primary Listing of XTL Biopharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • XTL Biopharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess XTL Biopharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. XTL Biopharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is XTL Biopharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as XTL Biopharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is XTL Biopharmaceuticals expected to grow at an attractive rate?
  • Unable to compare XTL Biopharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare XTL Biopharmaceuticals's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare XTL Biopharmaceuticals's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:H2K2 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 55.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 24%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:H2K2 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:H2K2 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 -1 -1
2019-09-30 1
2019-06-30 3
2019-03-31 6
2018-12-31 -1 3
2018-09-30 2
2018-06-30 2
2018-03-31 1
2017-12-31 -1 -1
2017-09-30 -1 -2
2017-06-30 -4
2017-03-31 -3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if XTL Biopharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if XTL Biopharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:H2K2 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from XTL Biopharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:H2K2 Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 0.00
2019-09-30 0.00
2019-06-30 0.01
2019-03-31 0.01
2018-12-31 0.01
2018-09-30 0.00
2018-06-30 0.00
2018-03-31 0.00
2017-12-31 0.00
2017-09-30 0.00
2017-06-30 -0.01
2017-03-31 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if XTL Biopharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine XTL Biopharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. XTL Biopharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. XTL Biopharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess XTL Biopharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
XTL Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has XTL Biopharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare XTL Biopharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • XTL Biopharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare XTL Biopharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare XTL Biopharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
XTL Biopharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from XTL Biopharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:H2K2 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 -1.35 0.81 0.04
2019-09-30 0.81 0.78 0.04
2019-06-30 3.10 0.77 0.04
2019-03-31 5.99 0.76 0.04
2018-12-31 2.99 0.76 0.04
2018-09-30 1.94 0.83 0.03
2018-06-30 2.49 0.83 0.03
2018-03-31 1.07 1.09 0.03
2017-12-31 -0.78 1.20 0.04
2017-09-30 -1.98 1.20 0.10
2017-06-30 -3.86 1.28 0.13
2017-03-31 -2.95 1.20 0.23
2016-12-31 -2.55 1.27 0.44
2016-09-30 -3.47 1.39 0.72
2016-06-30 -3.63 1.39 0.82
2016-03-31 -3.81 1.45 0.77
2015-12-31 -3.62 1.42 0.58
2015-09-30 -2.47 1.51 0.40
2015-06-30 -2.41 1.56 0.31
2015-03-31 -2.22 1.53 0.27
2014-12-31 -2.12 1.73 0.28
2014-09-30 -1.66 -0.95 -0.59 0.13
2014-06-30 -1.19 -0.02 -0.44 0.12
2014-03-31 2.28 -2.29 3.49 0.15
2013-12-31 -1.14 1.29 0.08
2013-09-30 2.25 -1.62 4.67 0.09
2013-06-30 2.12 -2.22 5.30 0.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if XTL Biopharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if XTL Biopharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if XTL Biopharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess XTL Biopharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
XTL Biopharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is XTL Biopharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up XTL Biopharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • XTL Biopharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • XTL Biopharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of XTL Biopharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • XTL Biopharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from XTL Biopharmaceuticals Company Filings, last reported 3 months ago.

DB:H2K2 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 6.98 0.00 6.73
2019-09-30 8.09 0.00 4.64
2019-06-30 9.35 0.00 4.76
2019-03-31 12.20 0.00 5.06
2018-12-31 8.32 0.00 8.12
2018-09-30 7.27 0.00 5.41
2018-06-30 6.24 0.00 5.46
2018-03-31 6.20 0.00 5.54
2017-12-31 3.62 0.00 6.09
2017-09-30 3.62 0.00 6.40
2017-06-30 2.09 0.00 6.33
2017-03-31 3.50 0.00 6.76
2016-12-31 2.69 0.00 2.43
2016-09-30 3.83 0.00 2.32
2016-06-30 4.08 0.00 2.97
2016-03-31 4.39 0.00 3.11
2015-12-31 4.89 0.00 4.07
2015-09-30 7.22 0.00 4.56
2015-06-30 7.63 0.00 5.10
2015-03-31 4.68 0.00 2.16
2014-12-31 4.68 0.00 2.16
2014-09-30 5.48 0.00 2.91
2014-06-30 5.85 0.00 3.26
2014-03-31 6.43 0.00 3.87
2013-12-31 6.79 0.00 4.17
2013-09-30 8.98 0.00 4.14
2013-06-30 8.00 0.00 2.05
  • XTL Biopharmaceuticals has no debt.
  • XTL Biopharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Information is not available.
  • Unable to confirm if XTL Biopharmaceuticals has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess XTL Biopharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. XTL Biopharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is XTL Biopharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from XTL Biopharmaceuticals dividends.
If you bought €2,000 of XTL Biopharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate XTL Biopharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate XTL Biopharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:H2K2 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as XTL Biopharmaceuticals has not reported any payouts.
  • Unable to verify if XTL Biopharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of XTL Biopharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as XTL Biopharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess XTL Biopharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can XTL Biopharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. XTL Biopharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of XTL Biopharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Doron Turgeman
AGE 51
TENURE AS CEO 0.3 years
CEO Bio

Mr. Doron Turgeman has been Chief Executive Officer at XTL Biopharmaceuticals Ltd. since January 29, 2020. Mr. Turgeman has been the Chief Executive Officer of Internet Gold Golden Lines Ltd. Mr. Turgeman served as the Chief Executive Officer of B Communications Ltd since October 02, 2011 until January 16, 2019. He had been Director of Bezeq The Israel Telecommunication Corp, Limited since March 26, 2018 until 2019. He served as Chief Financial Officer at Eurocom Communications Ltd. He served as the Chief Financial Officer of Internet Gold Golden Lines Ltd., since May 2001 and served as its Chief Accounting Officer. He served as the Chief Financial Officer of B Communications Ltd. since January 2008 until February 2010 and served as its Deputy Chief Executive Officer. He served as Deputy Chief Executive Officer of Internet Gold Golden Lines Ltd. and for its subsidiary Smile.Media Ltd. since October 2004. Mr. Turgeman served as the Chief Financial Officer of Goldmind Media Ltd., since January 2000 and served as its Deputy chief executive officer since October 2004. He served as Chief Financial Officer of Eurocom Digital Communications Ltd. Since January 2002, he served as Chief Executive Officer and Chief Financial Officer of Start Net Ltd., a company operated by MSN Israel. Mr. Turgeman served as Vice President of Finance at Internet Gold Golden Lines Ltd. since May 2001. He served as the Chief Financial Officer of Internet Gold's subsidiaries MSN Israel Ltd., and Gold Mind Ltd., since January 2000. He joined Internet Gold Golden Lines Ltd. in April 2001. From 1999 to 2000, he served as Controller of Bezeq-call Ltd. From 1997 to 1999, he served as Controller of the Post Office Bank. He has been a Non-Executive Director of XTL Biopharmaceuticals Ltd since December 30, 2014 and serves its Chairman Since January 2002, he served as Director of Start Net Ltd. He served as a Director of B Communications Ltd. since January 2008 until February 2010. He is a Certified Public Accountant in Israel. Mr. Turgeman holds a B.A. degree in Economics and Accounting from the Hebrew University.

CEO Compensation
  • Insufficient data for Doron to compare compensation growth.
  • Insufficient data for Doron to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team

Doron Turgeman

TITLE
Chairman & CEO
AGE
51
TENURE
0.3 yrs

Itay Weinstein

TITLE
Chief Financial Officer
AGE
48
TENURE
2.8 yrs

Ronen Kantor

TITLE
Company Secretary
Board of Directors Tenure

Average tenure and age of the XTL Biopharmaceuticals board of directors in years:

5.1
Average Tenure
55
Average Age
  • The tenure for the XTL Biopharmaceuticals board of directors is about average.
Board of Directors

Doron Turgeman

TITLE
Chairman & CEO
AGE
51
TENURE
1.8 yrs

Ossi Fain

TITLE
Non-Executive & External Director
AGE
53
TENURE
5.1 yrs

Jonathan Schapiro

TITLE
Non-Executive Director
AGE
59
TENURE
5.3 yrs

Dobroslav Melamed

TITLE
Non-Executive Director
AGE
42
TENURE
5.3 yrs

Shlomo Shalev

TITLE
Director
AGE
57
TENURE
5.3 yrs

Murray Urowitz

TITLE
Member of Clinical Advisory Board

Dan Wallace

TITLE
Member of Clinical Advisory Board

David Isenberg

TITLE
Member of Clinical Advisory Board
TENURE
4.6 yrs

Lee Simon

TITLE
Member of Clinical Advisory Board
AGE
68

Robert Fox

TITLE
Member of Clinical Advisory Board
TENURE
3.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess XTL Biopharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. XTL Biopharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren’s syndrome. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Ramat Gan, Israel.

Details
Name: XTL Biopharmaceuticals Ltd.
H2K2
Exchange: DB
Founded: 1993
₪5,114,483
514,205,799
Website: http://www.xtlbio.com
Address: XTL Biopharmaceuticals Ltd.
5 Badner Street,
Ramat Gan,
4365603,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TASE XTLB Ordinary Shares The Tel-Aviv Stock Exchange IL ILS 26. Sep 2000
NasdaqCM XTLB SPON ADS EACH REP 100 ORD SHS(POST SPLT) Nasdaq Capital Market US USD 01. Sep 2005
DB H2K2 SPON ADR EACH REP 100 ORD SHS(POST SPLT) Deutsche Boerse AG DE EUR 06. Apr 2020
DB H2K2 SPON ADS EACH REP 100 ORD SHS(POST SPLT) Deutsche Boerse AG DE EUR 01. Sep 2005
Number of employees
Current staff
Staff numbers
0
XTL Biopharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/06 01:31
End of day share price update: 2020/04/03 00:00
Last earnings filing: 2020/03/12
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.